Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Targeted Oncology
Published in: Targeted Oncology 6/2016

01-12-2016 | Retraction Note

Retraction Note to: MicroRNA-216b is Down-Regulated in Human Gastric Adenocarcinoma and Inhibits Proliferation and Cell Cycle Progression by Targeting Oncogene HDAC8

Authors: Ying Wang, Po Xu, Jun Yao, Ruina Yang, Zhenguo Shi, Xiaojuan Zhu, Xiaoshan Feng, Shegan Gao

Published in: Targeted Oncology | Issue 6/2016

Login to get access

Excerpt

Retraction note to: Targ Oncol (2016) 11:197–207 …
Metadata
Title
Retraction Note to: MicroRNA-216b is Down-Regulated in Human Gastric Adenocarcinoma and Inhibits Proliferation and Cell Cycle Progression by Targeting Oncogene HDAC8
Authors
Ying Wang
Po Xu
Jun Yao
Ruina Yang
Zhenguo Shi
Xiaojuan Zhu
Xiaoshan Feng
Shegan Gao
Publication date
01-12-2016
Publisher
Springer International Publishing
Published in
Targeted Oncology / Issue 6/2016
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-016-0470-5

Other articles of this Issue 6/2016

Targeted Oncology 6/2016 Go to the issue

Original Research Article

Phase 1 Study of CEP-37250/KHK2804, a Tumor-specific Anti-glycoconjugate Monoclonal Antibody, in Patients with Advanced Solid Tumors

Original Research Article

Early Tumor Shrinkage and Depth of Response as Predictors of Favorable Treatment Outcomes in Patients with Metastatic Colorectal Cancer Treated with FOLFOX Plus Cetuximab (JACCRO CC-05)

Original Research Article

Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines

Meeting Report

Annual Congress of the European Society for Medical Oncology (ESMO): Copenhagen, Denmark; 7–11 October 2016

Review Article

Will Testicular Germ Cell Tumors Remain Untargetable?

Systematic Review

Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits